#USA #Stockholm #Sobi #Gout Treatment #pozdeutinurad

Positive Phase 3 REDUCE 2 Study Results for Pozdeutinurad in Gout

Introduction

Sobi®, a global biopharmaceutical company, recently announced encouraging topline results from its pivotal Phase 3 REDUCE 2 clinical study concerning pozdeutinurad (AR882), a next-generation, selective URAT1 inhibitor aimed at treating gout. The study, which included a significant number of participants suffering from uncontrolled gout, sheds light on the potential of this new treatment option.

Study Overview

The REDUCE 2 study, a randomised, double-blind, placebo-controlled trial, enrolled 811 patients globally, most of whom were inadequately managed with current urate-lowering therapies. Participants were divided into three groups: one received 50 mg and another 75 mg doses of pozdeutinurad, while a placebo group was also included. The primary objective was to determine the proportion of patients achieving a serum uric acid (sUA) level below 6 mg/dL at the six-month mark.

Both dosages of pozdeutinurad met this critical efficacy endpoint remarkably well: 69.2% of patients on the 75 mg dose and 56.6% of those on the 50 mg dose managed to achieve this target level, in contrast to only 8.1% in the placebo group. Such outcomes indicate a significant therapeutic potential for individuals struggling to control their gout symptoms.

Safety Profile

The safety profile of pozdeutinurad has been consistent across studies. It was well-tolerated among participants, which raises hopes for its future approval and application as a viable gout treatment.

Commentary from the Experts

Dr. Lydia Abad-Franch, Chief Medical Officer at Sobi, expressed great optimism regarding the results, stating, “We are very encouraged by these results and their implications for patients whose gout remains inadequately controlled. These findings...support the potential of pozdeutinurad to address a significant unmet need.”

Future Directions

Pozdeutinurad has been included in Sobi's development portfolio following the acquisition of Arthrosi, Inc., a biotech firm focused on gout treatment. To strengthen its position in gout management, pozdeutinurad is currently being evaluated in another global Phase 3 study, REDUCE 1, which is already fully enrolled.

Understanding Gout

As the most prevalent form of inflammatory arthritis, gout occurs due to elevated uric acid levels, which cause painful flare-ups when crystals form in the joints. If uncontrolled, patients may face serious health complications, including chronic joint damage and other comorbidities such as kidney issues and cardiovascular risks. Current first-line therapies do not adequately address the needs of all patients, highlighting the critical demand for new treatments to alleviate their suffering and improve their quality of life.

Conclusion

The promising data emerging from the REDUCE 2 study suggest that pozdeutinurad could potentially revolutionise the approach to gout treatment by offering an effective alternative for patients who are not responding to existing therapies. As Sobi moves forward with regulatory submissions, the healthcare community eagerly awaits further insights from upcoming scientific congresses scheduled for the latter part of this year. Pozdeutinurad may soon emerge as an essential addition to the gout management arsenal, benefiting countless patients globally.

About Sobi

Sobi is dedicated to transforming the lives of those with rare diseases. As a leader in biopharmaceutical innovations, Sobi employs around 2,000 professionals in various countries and had a revenue of SEK 28 billion in 2025. For more information about Sobi and its advancements in biopharma, visit their official website.